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Purpose or Objective: To evaluate the patterns of 
recurrence and its value in target delineation for 
postoperative radiotherapy(PORT) in patients with stage III 
thoracic esophageal squmous cell carcinoma(ESCC) after 
esophagectomy. 
 
Material and Methods: 395 patients with stage III thoracic 
ESCC treated with radical esophagectomy from Jan, 2008 to 
Dec, 2011 were enrolled in this study. No patients has 
accepted preoperative adjuvant therapy. There were 302 
males and 93 females; median ages was 60 years old (range 
33-83). There were 33 patients located in upper-, 273 in 
middle- and 89 in low-segment. 375 patents has operated 
with two-field and 22 with three-field esophagectomy. The 
median number of dissected lymph nodes were 10 per case 
(range 1-34). There were 244 with stage IIIA, 106 with IIIB 
and 45 with IIIC. There were 97 patients received with 
surgery alone, 212 with postoperative chemotherapy(POCT), 
86 with PORT(30 with POCT and PORT). Diagnosis of 
recurrence was parimarily based on CT images, some of 
which were biopsy-confirmed. The location and time of 
tumor recurrences were analyzed. 
 
Results: The overall failure rates was 75.7%(299/395). 
Locoregional recurrence(LR) was found in 48.4% of patients, 
distant metastasis(DM) in 16.2%, and LR plus DM in 4.3%; the 
total rate of LR and DM were 52.7% and 20.5%, respectively. 
There were 208 patients recurred with LR, 26.9%(56) 
recurred in supraclavicular/neck(51 in supraclavicular), 69.7% 
(145) in mediastinum, and 19.7% (41) in upper abdomen (38 
in para-aortic lymph node). 92.8% of LR involved locoregional 
lymph nodes; the rate of anastomotic recurrence was 5.1% 
(20/395). Further analysis showed that upper-mediastinal 
recurrence accounted for 88.7% of mediastinal recurrence. 
The estimated 1-, 3-, and 5-year accumulated LR rates for all 
patients were 32.2%, 55.1% and 60.1%. Multivariate COX and 
logistic regression analysis showed that TNM stage and 
adjuvant therapy were independent factor for LR (p<0.05); 
PORT could reduce LR, especially in patients with middle-
thoracic segment, IIIA and IIIB disease, two-field 
esophagectomy, less than 6 dissected lymph node or severe 
adhesion at surgery (p<0.05); but POCT did not decrease LR. 
 
Conclusion: The recurrence rate was very high in stage III 
thoracic ESCC patients, LR was the main pattern of failure; 
TNM stage was one of the most important factor for LR. PORT 
could reduce LR but POCT could not. Upper-mediastinum was 
the most common site of recurrence, followed by 
supraclavicular and para-aortic regions; these areas should be 
consedered the key target of PORT. 
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Purpose or Objective: Aim of this study is the evaluation of 
feasibility and efficacy of SBRT in the treatment of 
unresectable hepatocellular carcinoma (HCC). 
 
Material and Methods: Patients with 1-3 inoperable HCC 
lesions with diameter ≤6cm were treated by SBRT. 
Prescription dose was 36-75Gy in 3-6 fractions. SBRT was 
delivered using the volumetric modulated arc therapy 
technique with flattening filter free photon beams. The 
primary end points of this study were in–field local control 
(LC) and toxicity. Secondary end points were overall survival 
(OS) and progression free survival (PFS). 
 
Results: From February 2011 and April 2015, 71 patients with 
102 HCC lesions were irradiated. All patients had Child-
Turcotte-Pugh class A or B disease. Median follow-up was 9 
months (range 5-43 months). Actuarial LC at 1 and 2-years 
was 92% and 81%. An Equivalent Dose >100Gy was a 
significant prognostic factor for LC in univariate analysis, 
with a 1-2 years LC rates of 99%-94% for a subgroup of lesions 
treated with a BED ≥100Gy and 58% -29% for lesions treated 
with a BED <100Gy (p<0.001). Median OS was 25 months. 
Actuarial OS at 1 and 2 years was 70% and 60%, respectively. 
Univariate analysis showed that OS is correlated with LC 
(p<0.02), BED>100 (p<0.05) and Cumulative GTV<5cm 
(p<0.04). Median PFS was 9 months. Grade ≥3 toxicity was 
observed in 7 patients (18%). No classic RILD was observed. 
 
Conclusion: Our study shows that SBRT is a safe and effective 
treatment for selected patients with inoperable HCC. Local 
control rates and toxicity profile were encouraging. 
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Purpose or Objective: In the TNM 7 staging, supraclavicular 
lymph nodes (SCN) are considered distant metastasis and thus 
prognostically unfavourable. This is one of the reasons for a 
generally accepted policy to treat these patients with 
supraclavicular disease spread and without further distant 
metastases with definitive chemoradiation (dCRT), 
irrespective of N stage. However, the worse prognostic value 
of a supraclavicular disease may be questioned. We analysed 
the prognostic value of supraclavicular disease in dCRT for 
esophageal cancer. 
 
Material and Methods: We retrospectively analyzed 207 
patients treated between 2003 and 2013 with a standardized 
protocol of definitive chemoradiation (dCRT) for esophageal 
cancer to identify the prognostic value of metastasis in the 
supraclavicular lymphnodes on treatment failure and 
survival, with special attention to the relation between 
supraclavicular disease and N stage. All patients were treated 
with external beam radiotherapy (50.4 Gy in 28 fractions) 
combined with weekly concurrent paclitaxel 50 mg/m2and 
carboplatin AUC2. 
 
Results: Median follow up time for patients alive was 43.3 
months The median overall survival (OS) for all patients was 
17.5 months. OS at 1, 3 and 5 year was 67%, 36.1% and 21.3% 
respectively. For patients with a metastasis in a 
supraclavicular lymph node, overall survival was 23.6 months 
compared to 17.1 months for patients without a metastasis in 
the SCN (p=0.51). In multivariate analyses , higher cT status, 
cNstatus and tumor length were found prognostically 
unfavorable, but a positive supraclavicular lymph node was 
not of independent prognostic value for survival (p=0.67). 
The relationship between SCN involvement and N stage was 
analyzed separately. Median OS for tumors with SCN 
involvement and N0/1 disease was 49.0 months (15.4-82.6) 
compared to 17.4 months in patients with N2/3 disease 
(95%CI 99-24.8 p=0.097). Median diseasefree survival (DFS) 
for tumors with SCN involvement and N0/1 disease was 51.6 
months (95%CI 0-108.5) compared to 8.2 months in the N2/3 
group (95%CI 6.2-10.1 p=0.028). No significant difference in 
S330                                                                                                                                                    ESTRO 35 2016 
______________________________________________________________________________________________________ 
toxicity was seen between patients with SCN involvement and 
those without,irrespective of the location of the primary 
tumor.  
 
Conclusion: In esophageal cancer treated with definitive 
chemoradiation, number of affected lymph nodes is an 
important prognostic factor, while involvement of a 
supraclavicular lymph node is not. The supraclavicular lymph 
node should beconsidered a regional lymph node and treated 
with curative intend if the total number of involved lymph 
nodes is limited, irrespective of the site of the primary 
tumor. 
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Purpose or Objective: To define the role of radiation dose 
on overall survival (OS) in pancreatic adenocarcinoma (PAC) 
patients treated with adjuvant chemoradiotherapy (CRT). 
 
Material and Methods: A total of 518 patients from different 
centers, completely resected with macroscopically negative 
margins (R0-1) for PAC (T1-3; N0-1; M0) and treated with 
adjuvant CRT, were retrospectively reviewed. Patients with 
metastatic or unresectable disease at surgery, macroscopic 
residual disease (R2), treated with intraoperative 
radiotherapy (IORT), dead within 60 days of surgery and 
without a histological diagnosis of ductal carcinoma were 
excluded. Only 142 patients received adjuvant 
chemotherapy. 
 
Results: With 35 months of median follow-up, median OS was 
23.0 months after adjuvant CRT with dose ≥ 45 Gy versus 
13.0 months with dose < 45 Gy (p < 0.001); 5-year OS was 
21.9% versus 3.8%, respectively. Among prognostic factors, 
higher Ca19-9 levels (>90; p<0.001), higher tumor grade (G3-
4, p = 0.017), R1 resection (p = 0.003), higher pT stage (p = 
0.002) and positive nodes (p < 0.001) can be identified as 
negative. Multivariate analysis (HR: 0.52, 0.34-0.77; p = 
0.001) proved the positive impact of higher dose.  
 
Conclusion: A significant impact of CRT dose on OS was 
pointed out by the results of this analysis. The randomized 
trials on adjuvant CRT in PAC, in which a relatively low-dose 
of radiation (40 Gy, split course) was used, may have had 
conflicting results due to this bias.  
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Purpose or Objective: To compare long-term outcomes of 
chemoradiotherapy between young and elderly (≥70 years) 
oesophageal cancer patients treated with curative intent. 
 
Material and Methods: Oesophageal cancer patients treated 
between 1998 and 2013 in our institute with neoadjuvant 
(nCRT) or definitive (dCRT) chemoradiotherapy were 
retrospectively analysed. nCRT consisted of 36-50Gy with 
concurrent 5-fluorouracil/cisplatin or 41.4Gy with concurrent 
carboplatin/paclitaxel. dCRT consisted of 50Gy with 
concurrent fluorouracil/cisplatin or 50.4Gy with concurrent 
carboplatin/paclitaxel. Overall survival (OS), disease-free 
survival (DFS) and locoregional control (LRC) were compared 
between older (>70 years) and younger patients (< 70 years). 
Cox models were used to obtain adjusted hazard ratios (HR) 
and 95% confidence intervals (CI). 
 
Results: The cohort consisted of 253 patients with a median 
follow up of 4.3 years. A group of 182 patients (72%) was < 70 
years (median age 60). The remaining 71 patients were >70 
years (median age 75). The two age groups (younger vs. 
older) differed significantly regarding smoking (59% vs. 31%; 
p<0.001), alcohol abuse (64% vs. 46%; p=0.007), Charlson 
comorbidity index (median 0 vs. 1; p=0.001) and weight loss 
prior to CRT (median 4 vs. 3 kgs; p=0.038). Most patients had 
stage IIA-IIIA disease (82%). Distribution of tumour stages was 
similar in the two age groups (stage IIA: 27% vs. 24%, stage 
IIB: 4% vs. 4%, stage IIIA: 51% vs. 55%).  
Initial treatment was nCRT with the intent to proceed to 
surgery in 169 patients, whereas 84 patients were planned 
for dCRT. Although surgery was the intent, 15% of the 
younger nCRT patients were not operated versus 35% of the 
older nCRT patients (p=0.01). Reasons to withhold surgery in 
the younger versus older patients were tumour progression 
(10% vs. 14%), toxicity (2% vs. 11%) or patient's own choice 
(3% vs. 11%), p=0.01. At baseline, there was a significant 
difference in the distribution of the final treatment given 
(nCRT + surgery, dCRT or nCRT without surgery; p<0.001).  
For the entire study population, OS at 3-years was 42%. In the 
multivariable analysis, no difference was found in OS 
between the two age groups (old vs. young; HR 0.72, 95% CI 
0.49–1.07, p=0.10). In the older age group, DFS (HR 0.66, 95% 
CI 0.45–0.98, p=0.04) and LRC (HR 0.43, 95% CI 0.23–0.82, 
p=0.01) were significantly better than in the younger age 
group. 
 
Conclusion: Elderly oesophageal cancer patients (>70 years) 
treated with neoadjuvant chemoradiotherapy followed by 
surgery or definitive chemoradiotherapy had long-term 
outcomes which did not differ from the outcomes of their 
younger counterparts. For oesophageal cancer patients, 
advanced age alone should not be a contraindication for 
chemoradiotherapy as a part of treatment with curative 
intent. 
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